Urinalysis of MMX-mesalazine as a tool to monitor 5-ASA adherence in daily IBD practice.
Tessa E H RömkensRene Te MorscheWilbert PetersDavid Marinus BurgerFrank HoentjenJoost P H DrenthPublished in: British journal of clinical pharmacology (2017)
Adherence is pivotal but challenging in ulcerative colitis (UC) treatment. Many methods to assess adherence are subjective or have limitations. (Nac-)5-aminosalicylic acid (5-ASA) urinalysis by high-performance liquid chromatography (HPLC) seems feasible and reproducible in healthy volunteers. We performed a prospective study in adult quiescent UC patients to evaluate the feasibility of spot (Nac-)5-ASA urinalysis by HPLC to assess adherence in daily inflammatory bowel disease (IBD) care. Twenty-nine patients (51.7% male, mean age 52 ± 11 years) were included (median FU 9 months) and weekly spot urine samples were collected. We found large variation in spot (Nac-)5-ASA urinary excretion that was unrelated to brand, dosing schedule or dosage of 5-ASA. In conclusion, spot (Nac-)5-ASA urinalysis is not applicable to assess 5-ASA adherence in daily IBD care.
Keyphrases
- high performance liquid chromatography
- ulcerative colitis
- transcription factor
- healthcare
- end stage renal disease
- simultaneous determination
- newly diagnosed
- ms ms
- ejection fraction
- mass spectrometry
- tandem mass spectrometry
- solid phase extraction
- physical activity
- quality improvement
- prognostic factors
- primary care
- palliative care
- type diabetes
- depressive symptoms
- metabolic syndrome
- patient reported outcomes
- insulin resistance
- adipose tissue
- patient reported
- chronic pain
- replacement therapy
- smoking cessation